Asparlas 3,750 unit/5 ML vial 5ML
Ended Awarded
- Contract number
- SPE2DR26FMDT7
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $19,696
Award facts
- Contract value 100% obligated
- $19,695.92 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order valued at $19,695.92 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Asparlas (3,750 units of 5 ml vials). The delivery order, issued on October 27, 2025, with an ultimate completion date of November 18, 2025, utilizes firm fixed-price pricing and does not include a set-aside designation. DMS Pharmaceutical Group is performing at its Park Ridge, Illinois location and was selected to fulfill this pharmaceutical supply requirement through its established contracting relationship with DLA's Medical Supply Chain division.
This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, designated as contract SPE2DR. That master contract, awarded on November 13, 2025, carries a ceiling value of $499.999 billion and extends through December 31, 2036, positioning DMS Pharmaceutical Group as a critical regional pharmaceutical supplier supporting Department of Defense military healthcare facilities worldwide. The PPV-G GEN V program represents part of a broader $30.3 billion acquisition strategy enabling DLA to issue delivery orders for a comprehensive range of pharmaceutical products, including branded and generic prescription drugs, biologics, and medical consumables to meet recurring medical supply needs across the global military medical system.
Quick answers
Who was awarded contract SPE2DR26FMDT7?
SPE2DR26FMDT7 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on October 27, 2025.
How much is contract SPE2DR26FMDT7 worth?
The government has obligated $19,696 on SPE2DR26FMDT7.
Is contract SPE2DR26FMDT7 an order under another contract?
Yes. SPE2DR26FMDT7 is a delivery order under SPE2DR25D9114, an indefinite delivery contract.
Was contract SPE2DR26FMDT7 competed?
The extent of competition for SPE2DR26FMDT7 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award